Dropbox Demystified...
Health Care: Drugs
Amarantus Bioscience Holdings Inc (AMBS: OTC)
$0.04 0.00 | 0.23%
05/23/13 - 09:35 AM ET
44.40K / 5.04M
Vol / Avg. Vol:0.04 / 0.04
Open / Prev. Close:0.04 - 0.04
Today's Range:0.00 - 0.20
52 Wk Range:0.00%
Performance YTD:TheStreet Rating:
Portfolios with AMBS
- Portfolio NameUser Type
Latest AMBS Headlines from TheStreet
Press Releases for AMBS
- Amarantus To Present At The 2nd Annual Marcum MicroCap Conference On May 30 - PR Newswire 05.20.13 | 08:05 am
- Amarantus BioScience Reports Positive MANF Data In Neuroprotection Animal Models Of Parkinson’s Disease - Business Wire 03.27.13 | 07:03 am
- Amarantus BioScience Obtains Cessation Of Unauthorized Listing On Berlin-Bremen Stock Exchange - Business Wire 03.20.13 | 08:03 am
- Amarantus BioScience Appoints Mark Benedyk, Ph.D., To Board Of Directors - Business Wire 03.18.13 | 08:03 am
- Amarantus BioScience, Brewer Sports International And TCMG Announce #C4CT Concussion Awareness Conference - Business Wire 03.05.13 | 08:03 am
- Amarantus BioScience To Present MANF Parkinson's Data At The 15th Annual American Society For Experimental NeuroTherapeutics - PR Newswire 02.28.13 | 08:02 am
- Amarantus BioScience And Banyan Biomarkers To Present Poster Of MANF Data At The 3rd Annual Traumatic Brain Injury Conference - PR Newswire 02.25.13 | 10:02 am
- Amarantus BioScience To Present At The 15th Annual BIO CEO & Investor Conference - PR Newswire 02.08.13 | 08:02 am
- OneMedPlace Research Releases Update To Research Report On Amarantus BioScience - PR Newswire 02.06.13 | 09:02 am
- Amarantus BioScience Reports Statistical Significance Achieved For MANF Striatal Reinnervation In Neurorestoration Animal Model Of Parkinson's Disease - PR Newswire 02.04.13 | 09:02 am
Partner Headlines for AMBS
